MCID: LKM071
MIFTS: 75

Leukemia, Chronic Lymphocytic

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Leukemia, Chronic Lymphocytic

MalaCards integrated aliases for Leukemia, Chronic Lymphocytic:

Name: Leukemia, Chronic Lymphocytic 57 75 38 40
Chronic Lymphocytic Leukemia 38 12 76 53 37 29 6 43 15 73
Cll 57 12 53 75
B-Cell Chronic Lymphocytic Leukemia 12 59 75
B-Cell Chronic Lymphoid Leukemia 12 59
Chronic Lymphatic Leukemia 12 75
Lymphoplasmacytic Leukemia 12 73
Small Lymphocytic Lymphoma 59 73
Leukemia, Lymphocytic, Chronic, B-Cell 44
Lymphocytic Leukemia Chronic B-Cell 55
Leukemia, Lymphocytic, Chronic 53
Leukemia Lymphocytic Chronic 55
Leukemia, Chronic Lymphatic 57
Lymphoma Small Lymphocytic 55
Chronic Lymphoid Leukemia 75
B-Cll 59

Characteristics:

Orphanet epidemiological data:

59
b-cell chronic lymphocytic leukemia
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: Adult;

OMIM:

57
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
associated with susceptibility loci on chromosome 11p11 (clls1, ), 13q14 (clls2, ), 9q34.1 (clls3, ), 6p25.3 (clls4, ), and 11q24.1 (clls5, )


HPO:

32
leukemia, chronic lymphocytic:
Inheritance somatic mutation autosomal dominant somatic cell mutation


Classifications:



External Ids:

OMIM 57 151400
Disease Ontology 12 DOID:1040
ICD10 33 C91.1 C91.10
ICD9CM 35 204.1
MeSH 44 D015451
NCIt 50 C3163
Orphanet 59 ORPHA67038
UMLS via Orphanet 74 C0855095 C1868683 C0023434
ICD10 via Orphanet 34 C91.1
MESH via Orphanet 45 D015451
MedGen 42 C0023434
KEGG 37 H00005
SNOMED-CT via HPO 69 124975008

Summaries for Leukemia, Chronic Lymphocytic

MedlinePlus : 43 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In chronic lymphocytic leukemia (CLL), there are too many lymphocytes, a type of white blood cell. CLL is the second most common type of leukemia in adults. It often occurs during or after middle age, and is rare in children. Usually CLL does not cause any symptoms. If you have symptoms, they may include Painless swelling of the lymph nodes in the neck, underarm, stomach, or groin Fatigue Pain or a feeling of fullness below the ribs Fever and infection Weight loss Tests that examine the blood, bone marrow, and lymph nodes diagnose CLL. Your doctor may choose to just monitor you until symptoms appear or change. Treatments include radiation therapy, chemotherapy, surgery to remove the spleen, and targeted therapy. Targeted therapy uses substances that attack cancer cells or block the growth and spread of cancer cells. NIH: National Cancer Institute

MalaCards based summary : Leukemia, Chronic Lymphocytic, also known as chronic lymphocytic leukemia, is related to cll/sll and leukemia, acute myeloid, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Leukemia, Chronic Lymphocytic is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Arzerra and Campath have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are cellular immunodeficiency and chronic lymphatic leukemia

Disease Ontology : 12 A lymphoblastic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood.

NIH Rare Diseases : 53 Chronic lymphocytic leukemia (CLL) is a cancer of the lymphocytes (a type of white blood cell). It begins in the stem cells of the bone marrow and then spreads to the blood. Over time, CLL may also spread to the lymph nodes and other organs, including the liver, spleen and lungs. Early signs and symptoms of CLL may include swollen lymph nodes, fatigue, weight loss, loss of appetite, fever, night sweats and/or frequent infections. The underlying cause of CLL is unknown. It usually occurs in people with no family history of the condition, but familial cases have been reported. Treatment options depend on many factors, including the stage of the condition, blood cell counts, and whether the CLL has recurred (come back). Treatment may not be necessary until a person develops symptoms or there is other evidence of rapid cancer progression. The chance of recovery and life expectancy vary from person to person. While most people with CLL live at least 5 to 10 years, some do not survive more than 2 to 3 years after the diagnosis.

OMIM : 57 Chronic lymphocytic leukemia (CLL) is a common neoplasia of B lymphocytes in which these cells progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival (summary by Quesada et al., 2012). (151400)

UniProtKB/Swiss-Prot : 75 Leukemia, chronic lymphocytic: A chronic leukemia in which functionally incompetent B-lymphocytes progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival.

Wikipedia : 76 Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many... more...

Related Diseases for Leukemia, Chronic Lymphocytic

Diseases in the Acute Lymphocytic Leukemia family:

Leukemia, Chronic Lymphocytic 2 Leukemia, Chronic Lymphocytic
Leukemia, Chronic Lymphocytic 1 Leukemia, Chronic Lymphocytic 3
Leukemia, Chronic Lymphocytic 4 Leukemia, Chronic Lymphocytic 5
Adult Acute Lymphocytic Leukemia

Diseases related to Leukemia, Chronic Lymphocytic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Related Disease Score Top Affiliating Genes
1 cll/sll 35.5 ATM CCND1 TP53
2 leukemia, acute myeloid 31.8 HRAS MIR181A2 MIR424 NRAS TP53
3 leukemia, chronic lymphocytic 2 12.4
4 leukemia, chronic lymphocytic 4 12.2
5 leukemia, chronic lymphocytic 5 12.2
6 leukemia, chronic lymphocytic 1 12.2
7 leukemia, chronic lymphocytic 3 12.2
8 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 12.2
9 pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 12.2
10 colorectal cancer 11.9 ATM BRAF CCND1 HRAS MIR106B MIR107
11 lung cancer 11.9 ATM BRAF CCND1 HRAS MIR107 MIR143
12 hepatocellular carcinoma 11.9 CCND1 HRAS MIR106B MIR107 MIR143 MIR145
13 pancreatic cancer 11.8 CCND1 HRAS MIR107 MIR143 MIR15A MIR16-1
14 myeloma, multiple 11.8 BRAF CCND1 HRAS IKZF3 MIR106B MIR15A
15 prostate cancer 11.8 CCND1 HRAS MIR106B MIR143 MIR145 MIR15A
16 glioblastoma 11.7 BRAF CCND1 HRAS MIR181A2 MIR34A NRAS
17 glioma 11.7 BRAF CCND1 MIR15A MIR181A2 MIR34A POT1
18 ovarian cancer 11.7 ATM BRAF CCND1 MIR106B MIR15A MIR29A
19 melanoma 11.7 BRAF MIR107 MIR15A MIR181A2 MIR34A NRAS
20 squamous cell carcinoma, head and neck 11.7 BRAF CCND1 HRAS MIR15A MIR424 TP53
21 renal cell carcinoma, papillary, 1 11.7 ATM BRAF HRAS NRAS TP53
22 gastric cancer 11.7 CCND1 MIR106B MIR107 MIR143 MIR145 MIR34A
23 bladder urothelial carcinoma 11.7 BRAF CCND1 HRAS NRAS TP53
24 thyroid cancer, nonmedullary, 1 11.7 BRAF MIR15A MIR181A2 MIR29A MIR34A
25 lymphoma, non-hodgkin, familial 11.6 ATM BRAF CCND1 NRAS TP53
26 ovarian serous cystadenocarcinoma 11.6 BRAF HRAS NRAS TP53
27 lung cancer susceptibility 3 11.6 BRAF CCND1 HRAS NRAS TP53
28 gastric adenocarcinoma 11.6 BRAF CCND1 HRAS NRAS TP53
29 melanoma, cutaneous malignant 1 11.6 HRAS NRAS POT1 TP53
30 differentiated thyroid carcinoma 11.6 BRAF HRAS NRAS TP53
31 cell type cancer 11.6 CCND1 HRAS NRAS TP53
32 skin melanoma 11.6 BRAF HRAS NRAS TP53
33 spitz nevus 11.6 BRAF HRAS TP53
34 synchronous bilateral breast carcinoma 11.6 ATM CCND1 TP53
35 meningeal melanomatosis 11.6 HRAS NRAS TP53
36 mantle cell lymphoma 11.6 ATM CCND1 MIR16-1 TP53
37 thyroid cancer 11.6 BRAF CCND1 HRAS NRAS TP53
38 ovarian serous carcinoma 11.6 MIR143 MIR145 MIR29A
39 oral squamous cell carcinoma 11.6 MIR143 MIR145 MIR29A MIR34A
40 liver angiosarcoma 11.6 HRAS NRAS TP53
41 esophagus adenocarcinoma 11.5 MIR143 MIR145 TP53
42 gastrointestinal system benign neoplasm 11.5 CCND1 HRAS TP53
43 skin squamous cell carcinoma 11.5 BRAF HRAS TP53
44 intestinal benign neoplasm 11.5 CCND1 HRAS TP53
45 nonalcoholic fatty liver disease 11.5 MIR107 MIR16-1 MIR34A
46 penile cancer 11.5 CCND1 HRAS TP53
47 integumentary system cancer 11.5 HRAS NRAS TP53
48 brain cancer 11.5 BRAF HRAS NRAS TP53
49 cell type benign neoplasm 11.5 CCND1 HRAS TP53
50 suppression of tumorigenicity 12 11.5 BRAF HRAS TP53

Comorbidity relations with Leukemia, Chronic Lymphocytic via Phenotypic Disease Network (PDN): (show all 14)


Acquired Thrombocytopenia Acute Cystitis
Agammaglobulinemia, X-Linked Anemia, Autoimmune Hemolytic
Bronchitis Chronic Leukemia
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1
Leukemia Lymphoblastic Leukemia
Lymphoid Leukemia Neutropenia

Graphical network of the top 20 diseases related to Leukemia, Chronic Lymphocytic:



Diseases related to Leukemia, Chronic Lymphocytic

Symptoms & Phenotypes for Leukemia, Chronic Lymphocytic

Symptoms via clinical synopsis from OMIM:

57
Hematology:
chronic lymphatic leukemia

Laboratory Abnormalities:
recurring t(11,14) and t(14,19)(q32,q13.1) translocations

Immunology:
impaired cellular and humoral immunity


Clinical features from OMIM:

151400

Human phenotypes related to Leukemia, Chronic Lymphocytic:

32
# Description HPO Frequency HPO Source Accession
1 cellular immunodeficiency 32 HP:0005374
2 chronic lymphatic leukemia 32 HP:0005550

UMLS symptoms related to Leukemia, Chronic Lymphocytic:


angina pectoris, chest pain, edema, fatigue

MGI Mouse Phenotypes related to Leukemia, Chronic Lymphocytic:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 ATM BRAF CCND1 HRAS IKZF3 NRAS

Drugs & Therapeutics for Leukemia, Chronic Lymphocytic

FDA approved drugs:

(show all 9)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
2
Campath 18 49 ALEMTUZUMAB Berlex Laboratories May 2001
3
Clolar 18 49 CLOFARABINE Genzyme December, 2004
4
Gazyva 18 49 OBINUTUZUMAB Genentech October of 2013
5
Imbruvica 18 49 IBRUTINIB Pharmacyclics November of 2013/February 2014
6
Revlimid 18 49 LENALIDOMIDE Celgene June 2013
7
Rituxan 18 49 RITUXIMAB Biogen IDEC, Genentech November 1997
8
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
9
Zydelig 18 49 IDELALISIB Gilead July 2014

Drugs for Leukemia, Chronic Lymphocytic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 582)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
3
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53910-25-1 40926 439693
4
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
5
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1 305-03-3 2708
6
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
7
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
8
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
9
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
10
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
13
Valganciclovir Approved, Investigational Phase 4,Phase 2,Not Applicable 175865-60-8 64147
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
15
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
16 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Vaccines Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
21 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Bendamustine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
28 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
29 Epoetin alfa Phase 4,Phase 3,Phase 2,Phase 1 113427-24-0
30 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
31 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
34 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
40 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1729)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
2 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
3 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4 Valganciclovir
4 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
5 A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status Completed NCT01283386 Phase 4 chlorambucil;cyclophosphamide;fludarabine;rituximab [MabThera]
6 A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
7 Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) Completed NCT00802737 Phase 4 Ofatumumab
8 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
9 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
10 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
11 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
12 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Not yet recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
13 A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Terminated NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
14 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4 Epoetin Beta
15 Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3 FFP+HDMP+Rituximab
16 Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia Unknown status NCT01657955 Phase 3 Bendamustine Hydrochloride Injection;Chlorambucil
17 Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
18 A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment Unknown status NCT01678430 Phase 3 Ofatumumab;Chlorambucil;Bendamustine
19 The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases Unknown status NCT01518959 Phase 3 Cholecalciferol;oleum neutralicum
20 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
21 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
22 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
23 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
24 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
25 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
26 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
27 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
28 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
29 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
30 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
31 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
32 Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia Completed NCT00276848 Phase 3 Fludarabine plus Cyclophosphamide;Fludarabine
33 Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia Completed NCT00931645 Phase 3
34 Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
35 Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00262795 Phase 3 Fludarabine;Chlorambucil
36 FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia Completed NCT00769522 Phase 3 Bendamustine;Cyclophosphamide;Fludarabine
37 Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia Completed NCT01500083 Phase 3 Bendamustine at a dose of 100 mg/m2;Bendamustine at a dose of 120 mg/m2
38 Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) Completed NCT01423032 Phase 2, Phase 3 bendamustine;Fludarabine
39 FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients Completed NCT00090051 Phase 3 Rituximab;Fludarabine Phosphate;Cyclophosphamide
40 A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) Completed NCT01580228 Phase 3 Dinaciclib;Ofatumumab
41 A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) Completed NCT01539512 Phase 3 Idelalisib;Rituximab;Placebo to match idelalisib
42 Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia Completed NCT00281892 Phase 3 Fludarabine mono
43 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
44 Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Completed NCT00086580 Phase 3
45 Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia Completed NCT00824265 Phase 3 OFC Infusion;FC infusion
46 Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
47 Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Completed NCT00275054 Phase 3 Fludarabine;Cyclophosphamide
48 Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116 Completed NCT01539291 Phase 3 Idelalisib
49 Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Completed NCT00024440 Phase 3 cyclophosphamide;fludarabine phosphate
50 Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia Completed NCT00281918 Phase 3 Rituximab;Cyclophosphamide;Fludarabine Phosphate

Search NIH Clinical Center for Leukemia, Chronic Lymphocytic

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Chronic Lymphocytic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Leukemia, Chronic Lymphocytic:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Leukemia, Chronic Lymphocytic:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: leukemia, lymphocytic, chronic, b-cell

Genetic Tests for Leukemia, Chronic Lymphocytic

Genetic tests related to Leukemia, Chronic Lymphocytic:

# Genetic test Affiliating Genes
1 Chronic Lymphocytic Leukemia 29

Anatomical Context for Leukemia, Chronic Lymphocytic

MalaCards organs/tissues related to Leukemia, Chronic Lymphocytic:

41
B Cells, Bone, Bone Marrow, T Cells, Myeloid, Lymph Node, Spleen
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Chronic Lymphocytic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease

Publications for Leukemia, Chronic Lymphocytic

Articles related to Leukemia, Chronic Lymphocytic:

(show top 50) (show all 3406)
# Title Authors Year
1
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. ( 29934061 )
2018
2
Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib. ( 29760835 )
2018
3
Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations. ( 29449433 )
2018
4
A Chronic Lymphocytic Leukemia Patient with Progressive Multifocal Leukoencephalopathy Caused by John Cunningham Virus. ( 29950535 )
2018
5
Simultaneous finding of chronic lymphocytic leukemia and residual hairy cell leukemia using a lymphocyte-binding anti-CD antibody microarray. ( 29636954 )
2018
6
Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia? ( 29402474 )
2018
7
Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma. ( 29415977 )
2018
8
Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. ( 29976738 )
2018
9
Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia. ( 29911929 )
2018
10
Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia. ( 29277764 )
2018
11
Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation. ( 29450641 )
2018
12
Necrobiotic xanthogranuloma associated with chronic lymphocytic leukemia. ( 29485184 )
2018
13
Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. ( 28565930 )
2018
14
Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab. ( 29526963 )
2018
15
Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia. ( 29976737 )
2018
16
Gamma heavy chain disease evolving during the progression of chronic lymphocytic leukemia. ( 29315075 )
2018
17
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness. ( 29762141 )
2018
18
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the Phase 3b GREEN study. ( 29976743 )
2018
19
Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL). ( 29437555 )
2018
20
Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study. ( 29444501 )
2018
21
Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells. ( 29432497 )
2018
22
A catalytically inactive gelatinase B/MMP-9 mutant impairs homing of chronic lymphocytic leukemia cells by altering migration regulatory pathways. ( 29080742 )
2018
23
Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. ( 28679298 )
2018
24
Refractory Abdominal Pain in a Patient with Chronic Lymphocytic Leukemia: Be Wary of Acquired Angioedema due to C1 Esterase Inhibitor Deficiency. ( 29545957 )
2018
25
Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16A years of epidemiological data from the province of Girona, Spain. ( 29383469 )
2018
26
Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro. ( 29353760 )
2018
27
Disseminated cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia. ( 29428267 )
2018
28
Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients. ( 29449436 )
2018
29
Paraneoplastic pemphigus with anti-desmocollin 3 autoantibodies and chronic lymphocytic leukemia. ( 29599682 )
2018
30
Synchronous hairy cell leukemia and chronic lymphocytic leukemia: a case report with a brief review of literature. ( 29963523 )
2018
31
Treatment Sequencing in a Chronic Lymphocytic Leukemia Patient with Central Nervous System Involvement. ( 29977629 )
2018
32
Siglec-6 on chronic lymphocytic leukemia cells is a target for post-allogeneic hematopoietic stem cell transplantation antibodies. ( 29980538 )
2018
33
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome. ( 28708231 )
2017
34
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. ( 28049639 )
2017
35
Plasma matrix metalloprotease 9 correlates with blood lymphocytosis, leukemic cell invasiveness, and prognosis in B-cell chronic lymphocytic leukemia. ( 28240053 )
2017
36
The distribution and potential prognostic value of SMAD protein expression in chronic lymphocytic leukemia. ( 28349818 )
2017
37
Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review. ( 29387498 )
2017
38
Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma presenting simultaneously with acquired hemophilia and warm autoimmune hemolytic anemia. ( 28670081 )
2017
39
Presentation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in a Warthin Tumor: Case Report and Literature Review. ( 28978260 )
2017
40
Paraneoplastic pemphigus associated with chronic lymphocytic leukemia: A case report. ( 28225504 )
2017
41
Venetoclax for the treatment of patients with chronic lymphocytic leukemia. ( 28492339 )
2017
42
Learning from the Failures of Drug Discovery in B-Cell Non-Hodgkin Lymphomas and Perspectives for the Future: Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma as Two Ends of a Spectrum in Drug Development. ( 28494631 )
2017
43
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia. ( 28931525 )
2017
44
Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia. ( 28509580 )
2017
45
Possible Role of Polymorphisms in TNFA, NFKB1, and CASP8 Gene Promoter Areas in the Development of Chronic Lymphocytic Leukemia. ( 28361429 )
2017
46
Update of the Grupo EspaA+ol de Leucemia LinfocA-tica CrA^nica clinical guidelines of the management of chronic lymphocytic leukemia. ( 28236475 )
2017
47
New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia. ( 28776453 )
2017
48
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia. ( 28503240 )
2017
49
Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes. ( 28888994 )
2017
50
Common nonmutational<i>NOTCH1</i>activation in chronic lymphocytic leukemia. ( 28314854 )
2017

Variations for Leukemia, Chronic Lymphocytic

ClinVar genetic disease variations for Leukemia, Chronic Lymphocytic:

6
(show top 50) (show all 206)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
3 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
4 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
5 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
6 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
7 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
8 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
9 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
10 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
11 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
12 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
13 BRAF NM_004333.4(BRAF): c.1391G> A (p.Gly464Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913348 GRCh37 Chromosome 7, 140481417: 140481417
14 BRAF NM_004333.4(BRAF): c.1391G> A (p.Gly464Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913348 GRCh38 Chromosome 7, 140781617: 140781617
15 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
16 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh38 Chromosome 7, 140753334: 140753334
17 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
18 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 GRCh38 Chromosome 7, 140753354: 140753354
19 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
20 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
21 BRAF NM_004333.4(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 GRCh37 Chromosome 7, 140453133: 140453133
22 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
23 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Likely pathogenic rs397516896 GRCh38 Chromosome 7, 140753355: 140753355
24 BRAF NM_004333.4(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 GRCh38 Chromosome 7, 140753333: 140753333
25 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275
26 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh38 Chromosome 12, 25227341: 25227341
27 FBXW7 NM_033632.3(FBXW7): c.1513C> T (p.Arg505Cys) single nucleotide variant Likely pathogenic rs149680468 GRCh37 Chromosome 4, 153247289: 153247289
28 FBXW7 NM_033632.3(FBXW7): c.1513C> T (p.Arg505Cys) single nucleotide variant Likely pathogenic rs149680468 GRCh38 Chromosome 4, 152326137: 152326137
29 FBXW7 NM_033632.3(FBXW7): c.1513C> T (p.Arg505Cys) single nucleotide variant Likely pathogenic rs149680468 NCBI36 Chromosome 4, 153466739: 153466739
30 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
31 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs121913254 GRCh38 Chromosome 1, 114713909: 114713909
32 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs121913254 NCBI36 Chromosome 1, 115058053: 115058053
33 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
34 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
35 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh38 Chromosome 17, 7673823: 7673823
36 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh37 Chromosome 17, 7577141: 7577141
37 PTPN11 NM_002834.4(PTPN11): c.214G> A (p.Ala72Thr) single nucleotide variant Likely pathogenic rs121918453 GRCh37 Chromosome 12, 112888198: 112888198
38 PTPN11 NM_002834.4(PTPN11): c.214G> A (p.Ala72Thr) single nucleotide variant Likely pathogenic rs121918453 GRCh38 Chromosome 12, 112450394: 112450394
39 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
40 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh37 Chromosome 11, 534285: 534285
41 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
42 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
43 TP53 NM_000546.5(TP53): c.713G> A (p.Cys238Tyr) single nucleotide variant Conflicting interpretations of pathogenicity rs730882005 GRCh38 Chromosome 17, 7674250: 7674250
44 TP53 NM_000546.5(TP53): c.713G> A (p.Cys238Tyr) single nucleotide variant Conflicting interpretations of pathogenicity rs730882005 GRCh37 Chromosome 17, 7577568: 7577568
45 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Likely pathogenic rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
46 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Likely pathogenic rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
47 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
48 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
49 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
50 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh37 Chromosome 17, 7577114: 7577114

Copy number variations for Leukemia, Chronic Lymphocytic from CNVD:

7 (show top 50) (show all 1219)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14042 1 103366560 104230405 Loss Chronic lymphocytic leukemia
2 14895 1 110954839 111582296 Loss Chronic lymphocytic leukemia
3 14947 1 111421057 111642223 Loss Chronic lymphocytic leukemia
4 15456 1 115719205 117399077 Loss Chronic lymphocytic leukemia
5 17206 1 141510591 145121245 Deletion Chronic lymphocytic leukemia
6 17207 1 141510591 145121245 Loss Chronic lymphocytic leukemia
7 18527 1 146265358 148164994 Gain Chronic lymphocytic leukemia
8 19758 1 151208615 155645185 Gain Chronic lymphocytic leukemia
9 20025 1 152611898 157344161 Loss Chronic lymphocytic leukemia
10 21378 1 158336749 159355008 Loss Chronic lymphocytic leukemia
11 21384 1 158391645 159433573 Loss Chronic lymphocytic leukemia
12 21385 1 158391645 189498990 Loss Chronic lymphocytic leukemia
13 23023 1 170758115 170759115 Loss Chronic lymphocytic leukemia
14 23030 1 170822660 170823660 Gain Chronic lymphocytic leukemia
15 23626 1 172107770 172108770 Gain Chronic lymphocytic leukemia
16 24171 1 176708253 177307399 Gain Chronic lymphocytic leukemia
17 25274 1 186459864 186720923 Loss Chronic lymphocytic leukemia
18 25359 1 187890295 188217703 Loss Chronic lymphocytic leukemia
19 25435 1 189143434 189363313 Gain Chronic lymphocytic leukemia
20 25473 1 189804292 192389810 Gain Chronic lymphocytic leukemia
21 25685 1 193314169 193528753 Gain Chronic lymphocytic leukemia
22 26789 1 202768030 203457313 Loss Chronic lymphocytic leukemia
23 26818 1 203067017 205298659 Loss Chronic lymphocytic leukemia
24 26975 1 204424298 206588789 Loss Chronic lymphocytic leukemia
25 28076 1 218313329 220732423 Loss Chronic lymphocytic leukemia
26 28130 1 218942571 219164038 Loss Chronic lymphocytic leukemia
27 28133 1 218959043 244561923 Loss Chronic lymphocytic leukemia
28 28265 1 220678511 222112407 Gain Chronic lymphocytic leukemia
29 28321 1 221304071 221582122 Gain Chronic lymphocytic leukemia
30 28577 1 223594083 225234079 Loss Chronic lymphocytic leukemia
31 28643 1 224353010 225571533 Loss Chronic lymphocytic leukemia
32 28702 1 224857883 233411748 Loss Chronic lymphocytic leukemia
33 29066 1 227299711 227518155 Loss Chronic lymphocytic leukemia
34 29113 1 227696842 233631743 Loss Chronic lymphocytic leukemia
35 29265 1 229664393 229947546 Gain Chronic lymphocytic leukemia
36 29501 1 232707626 233302391 Loss Chronic lymphocytic leukemia
37 31053 1 24943712 26054939 Loss Chronic lymphocytic leukemia
38 31193 1 25985121 29490451 Deletion Chronic lymphocytic leukemia
39 31425 1 27504484 28494376 Loss Chronic lymphocytic leukemia
40 32443 1 36783544 38823237 Loss Chronic lymphocytic leukemia
41 33495 1 45606989 46307302 Gain Chronic lymphocytic leukemia
42 34016 1 51545765 53346467 Loss Chronic lymphocytic leukemia
43 34255 1 54029769 55100800 Loss Chronic lymphocytic leukemia
44 34911 1 57712092 58034742 Gain Chronic lymphocytic leukemia
45 35379 1 62697088 63142732 Loss Chronic lymphocytic leukemia
46 35406 1 63335974 63596958 Gain Chronic lymphocytic leukemia
47 35407 1 63335974 63641668 Gain Chronic lymphocytic leukemia
48 36497 1 76364563 76710672 Loss Chronic lymphocytic leukemia
49 36890 1 82341866 82576806 Loss Chronic lymphocytic leukemia
50 36895 1 82581235 82812961 Loss Chronic lymphocytic leukemia

Expression for Leukemia, Chronic Lymphocytic

Search GEO for disease gene expression data for Leukemia, Chronic Lymphocytic.

Pathways for Leukemia, Chronic Lymphocytic

Pathways related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.82 BRAF CCND1 HRAS NRAS TP53
2 12.79 BRAF CCND1 HRAS NRAS TP53
3
Show member pathways
12.73 BRAF CCND1 HRAS NRAS TP53
4
Show member pathways
12.66 ATM BRAF CCND1 HRAS NRAS TP53
5
Show member pathways
12.47 BRAF CCND1 HRAS NRAS TP53
6
Show member pathways
12.45 BRAF HRAS NRAS TP53
7
Show member pathways
12.4 ATM HRAS NRAS TP53
8
Show member pathways
12.4 BRAF CCND1 HRAS NRAS TP53
9 12.33 ATM CCND1 HRAS NRAS TP53
10 12.24 CCND1 HRAS NRAS TP53
11
Show member pathways
12.24 ATM CCND1 MIR106B MIR16-1 TP53
12
Show member pathways
12.15 BRAF HRAS NRAS TP53
13
Show member pathways
12.13 BRAF HRAS NRAS TP53
14 12.13 BRAF CCND1 HRAS NRAS TP53
15 12.11 CCND1 HRAS NRAS TP53
16 12.11 ATM BRAF CCND1 TP53
17
Show member pathways
12.09 BRAF HRAS NRAS TP53
18 12.01 ATM CCND1 HRAS NRAS TP53
19 11.99 BRAF HRAS NRAS TP53
20 11.94 ATM CCND1 HRAS MIR106B MIR107 MIR143
21
Show member pathways
11.91 ATM BRAF CCND1 HRAS NRAS
22 11.9 CCND1 HRAS NRAS TP53
23 11.85 CCND1 HRAS NRAS
24 11.78 ATM CCND1 HRAS NRAS TP53
25
Show member pathways
11.76 BRAF HRAS NRAS
26 11.7 BRAF CCND1 HRAS NRAS TP53
27 11.65 ATM HRAS TP53
28 11.65 ATM CCND1 POT1
29 11.64 HRAS NRAS TP53
30 11.63 HRAS NRAS TP53
31
Show member pathways
11.63 BRAF HRAS NRAS
32 11.58 BRAF HRAS NRAS
33 11.42 ATM CCND1 TP53
34 11.42 BRAF CCND1 HRAS NRAS TP53
35 11.39 BRAF HRAS NRAS
36 11.27 BRAF HRAS NRAS
37 11.23 ATM CCND1 TP53
38 11.21 ATM HRAS NRAS TP53
39 11.13 ATM CCND1 MIR106B MIR145 MIR16-1 TP53
40 10.99 CCND1 HRAS NRAS
41 10.79 HRAS NRAS

GO Terms for Leukemia, Chronic Lymphocytic

Cellular components related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 IGHG1 MIR106B MIR107 MIR143 MIR15A MIR16-1

Biological processes related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.99 HRAS MIR15A MIR16-1 MIR29A TP53
2 positive regulation of apoptotic process GO:0043065 9.95 ATM MIR15A MIR16-1 MIR29A TP53
3 Ras protein signal transduction GO:0007265 9.8 HRAS NRAS TP53
4 negative regulation of protein kinase B signaling GO:0051898 9.76 MIR145 MIR29A MIR34A
5 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.74 MIR15A MIR16-1 MIR29A
6 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.71 MIR15A MIR16-1 MIR424
7 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.67 MIR15A MIR16-1 TP53
8 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.64 MIR16-1 MIR34A
9 replicative senescence GO:0090399 9.64 ATM TP53
10 determination of adult lifespan GO:0008340 9.63 ATM TP53
11 positive regulation of connective tissue replacement GO:1905205 9.63 MIR16-1 MIR34A
12 miRNA mediated inhibition of translation GO:0035278 9.63 MIR106B MIR145 MIR15A MIR16-1 MIR181A2 MIR29A
13 mitotic G1 DNA damage checkpoint GO:0031571 9.62 CCND1 TP53
14 negative regulation of telomerase activity GO:0051974 9.61 POT1 TP53
15 negative regulation of vascular endothelial growth factor signaling pathway GO:1900747 9.61 MIR16-1 MIR424
16 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.61 MIR15A MIR34A MIR424
17 angiotensin-activated signaling pathway GO:0038166 9.6 MIR143 MIR145
18 regulation of telomere maintenance via telomerase GO:0032210 9.58 ATM POT1
19 cellular response to gamma radiation GO:0071480 9.58 ATM HRAS TP53
20 aorta smooth muscle tissue morphogenesis GO:0060414 9.56 MIR143 MIR145
21 negative regulation of angiogenesis GO:0016525 9.56 MIR106B MIR143 MIR145 MIR15A MIR16-1 MIR29A
22 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.54 MIR15A MIR16-1 MIR424
23 negative regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000545 9.52 MIR16-1 MIR424
24 regulation of phenotypic switching GO:1900239 9.51 MIR143 MIR145
25 negative regulation of cell chemotaxis to fibroblast growth factor GO:1904848 9.48 MIR15A MIR16-1
26 negative regulation of endothelial cell chemotaxis to vascular endothelial growth factor GO:1904858 9.46 MIR16-1 MIR424
27 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.43 MIR15A MIR34A MIR424
28 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.32 MIR143 MIR145
29 gene silencing by miRNA GO:0035195 9.32 MIR106B MIR107 MIR143 MIR145 MIR15A MIR16-1

Molecular functions related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.32 MIR106B MIR107 MIR143 MIR145 MIR15A MIR16-1

Sources for Leukemia, Chronic Lymphocytic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....